Interchange of vaccine products; COVID-19; This spontaneous case was reported by a physician and describes the occurrence of COVID-19 (COVID-19) and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) in a 35-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Previously administered products included for Drug use for unknown indication: Pfizer / BioNTech (Dose Number: 1, Location of injection: Arm Left) on 30-Dec-2020, Pfizer / BioNTech (Dose Number: 2, Location of injection: Arm Left) on 20-Jan-2021, Pfizer / BioNTech (Dose Number: 3 and Location of injection: Arm Left) on 20-Aug-2021. Past adverse reactions to the above products included No adverse event with Pfizer / BioNTech, Pfizer / BioNTech and Pfizer / BioNTech. Concurrent medical conditions included Primary mediastinal large B-cell lymphoma (treatment completed 30-Mar-2021 and have remained in remission) since 03-Dec-2020 and Drug allergy (Allergic to unspecified drug.). Concomitant products included CITALOPRAM HYDROBROMIDE (CELEXA [CITALOPRAM HYDROBROMIDE]), BUPROPION HYDROCHLORIDE (WELLBUTRIN), FAMOTIDINE (PEPCID [FAMOTIDINE]), VITAMIN C [ASCORBIC ACID], OXYMETAZOLINE (AFRIN [OXYMETAZOLINE]), FLUTICASONE PROPIONATE, PARACETAMOL (TYLENOL) and IBUPROFEN for an unknown indication.    On 03-Apr-2022, the patient received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In May 2022, the patient experienced COVID-19 (COVID-19). On an unknown date, the patient experienced INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 24-May-2022 to 28-May-2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, COVID-19 (COVID-19) was resolving and INTERCHANGE OF VACCINE PRODUCTS (Interchange of vaccine products) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Patient had fatigue returned (milder than before) and congestion returned (worse than before) and also developed new symptom of cough.  The patient took other medications/products within 2 weeks of starting COVID-19 treatment. Device Date reported as 02-Jun-2022. COMPANY COMMENT: This is an spontaneous case concerning a 35-year-old female patient with medical history of Primary mediastinal large B-cell lymphoma (treatment completed 30-Mar-2021 and have remained in remission) since 03-Dec-2020, Drug allergy, Concomitant products included CITALOPRAM, BUPROPION, FAMOTIDINE, VITAMIN C, OXYMETAZOLINE, FLUTICASONE, PARACETAMOL, IBUPROFEN, Pfizer / BioNTech COVID-19 VACCINE ON 30-Dec-2020, 20-Jan-2021 and 20-Aug-2021 (3 doses) and PAXLOVID from 24-May-2022 to 28-May-2022 for COVID-19 treatment who experienced the unexpected  event of COVID-19 (AESI) and INTERCHANGE OF VACCINE PRODUCTS unknown days after  4th. dose of  mRNA-1273 vaccine. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report; Sender's Comments: COMPANY COMMENT: This is an spontaneous case concerning a 35-year-old female patient with medical history of Primary mediastinal large B-cell lymphoma (treatment completed 30-Mar-2021 and have remained in remission) since 03-Dec-2020, Drug allergy, Concomitant products included CITALOPRAM, BUPROPION, FAMOTIDINE, VITAMIN C, OXYMETAZOLINE, FLUTICASONE, PARACETAMOL, IBUPROFEN, Pfizer / BioNTech COVID-19 VACCINE ON 30-Dec-2020, 20-Jan-2021 and 20-Aug-2021 (3 doses) and PAXLOVID from 24-May-2022 to 28-May-2022 for COVID-19 treatment who experienced the unexpected  event of COVID-19 (AESI) and INTERCHANGE OF VACCINE PRODUCTS unknown days after  4th. dose of  mRNA-1273 vaccine. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report